

510(k) Summary StaXxTM XD System

APR 2 7 2006

I. Submitter Information

Spine Wave, Inc. Two Enterprise Drive Suite 302

Shelton, CT 06484

Telephone: 203-944-9494 Telefax: 203-944-9493

Contact:

Ronald K. Smith

Date Prepared:

March 5, 2006

II. Device Information

Trade name:

StaXxTM XD System

Common name: Classification:

Vertebral Body Replacement Class II per 21 CFR 888.3060

Classification Name: Spinal Intervertebral Fixation Orthosis

Product Code:

MOP

III. Device Information

The StaXx™ XD System is a vertebral body replacement device composed of wafers that are stacked into an expandable implant to adjust its height. The implant components are manufactured from PEEK-OPTIMA with 6% Barium Sulfate. The system also includes a delivery device to implant and expand the system. The device is offered in sizes ranging from 7mm to 30mm.

IV. Intended Use

The StaXxTM XD System is a vertebral body replacement device intended for use in the thoracolumbar spine (T1-L5) to replace and restore height of a collapsed, damaged, or unstable vertebral body or portion thereof, due to tumor or trauma (i.e., fracture). The system is to be placed bilaterally and used with bone graft and supplemental spinal fixation. The supplemental fixation system that is intended to be used with the StaXx™ XD System is the Stryker Xia® Spinal System.

V. Substantial equivalence

The StaXxTM XD System was demonstrated to be substantially equivalent to the VERTE-STACK™ Spinal System (Medtronic Sofamor Danek, K043566), the Blackstone™ PEEK VBR System (Blackstone Medical, Inc., K041939 and K033702), the PEEK Tetris™ System (SIGNUS Medical LLC, K031757), the Sustain Radiolucent Spacer (Globus Medical Inc., K040284) and The Wafer System (Spine Wave, K033303). In addition, mechanical testing demonstrated

KC52L70 Page 2 of 2

that the StaXxTM XD System meets the performance requirements for its intended use. Any differences between the StaXxTM XD System and the predicate devices do not affect the safety or effectiveness of this device.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 1 7 2006

Spine Wave, Inc. c/o Mr. Ronald K. Smith Director, Quality and Regulatory Affairs Two Enterprise Drive, Suite 302 Shelton, Connecticut 06484

Re: K052670

Trade/Device Name: StaXx[™] XD System Regulation Number: 21 CFR 888.3060

Regulation Name: Spinal intervertebral body fixation orthosis

Regulatory Class: Class II Product Code: MQP Dated: January 26, 2006 Received: January 27, 2006

Dear Mr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

Page 2 – Mr. Ronald K. Smith

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson Acting Director Division of General, Restorative and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

A. Indications for Use

510(k) Number (i	fknown): <u>K0526</u>	70	
Device Name:	StaXx TM XD System		
indications for Us	se:		
horacolumbar sp unstable vertebral system is to be pl fixation. The sup	ine (T1-L5) to replac body or portion ther aced bilaterally and u	e and restore eof, due to to sed with bor estern that is	ement device intended for use in the height of a collapsed, damaged, or almor or trauma (i.e., fracture). The ne graft and supplemental spinal intended to be used with the StaXx TM
			•
Prescription (Part 21 CFI	Use√ R 801 Subpart D)	AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
(PLEASE DO N		V THIS LINI OF NEEDEI	E-CONTINUE ON ANOTHER PAGE D)
C	Marl	196	Device/Évaluation (ODE)
·	(Division Si Division of (and Neurolo	General, Re	
	#10/1\\ \PY	_	052670